BASKING RIDGE, N.J., Oct. 5 /PRNewswire-FirstCall/ -- VioQuest Pharmaceuticals (OTC Bulletin Board: VQPH), a New Jersey-based biopharmaceutical company focused on acquiring, developing and commercializing targeted cancer therapeutics, announced today that it will present at the BIO InvestorForum on Thursday, October 11, 2007 at 2:00 p.m. Pacific Time at the Palace Hotel in the Sea Cliff Room in San Francisco. Daniel Greenleaf, VioQuest's president and CEO, is scheduled to give an overview of the Company.
The BioInvestor Forum is dedicated to public and private equity investors, research analysts, investment bankers and senior-level industry executives focused on investment trends and business development opportunities in life sciences
The 4th Annual BIO InvestorForum will showcase to the investment community public and venture-stage growth companies as well as those poised to join the growth "watch list" in the coming year.
About VioQuest Pharmaceuticals
VioQuest focuses on acquiring, developing, and commercializing targeted
late preclinical and early clinical stage therapies with unique mechanisms
of action primarily for oncology and infectious diseases. VioQuest has
three targeted drug candidates in clinical development: VQD-002 which
inhibits activation of Akt that is seen at abnormally high levels in
breast, ovarian, colorectal, pancreatic, and hematologic cancers;
Lenocta(TM), an inhibitor of specific protein tyrosine phosphatases
(PTPases), SHP-1 and SHP-2, which has shown compelling clinical and
biological activity in solid tumors and Xyfid(TM), a topical therapy which
has shown early clinical promise in the treatment and prevention of
chemo-induced Hand-Foot Syndrome (HFS). VioQuest anticipates commencing
several Phase II trials for VQD-002, Lenocta(TM) and Xyfid(TM) in the
|SOURCE VioQuest Pharmaceuticals|
Copyright©2007 PR Newswire.
All rights reserved